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Insulin resistance plays a major role in the pathophysiology
of diabetes and is associated with obesity and cardiovascular
disease. Excellent methods exist for the assessment of insulin
sensitivity in the laboratory setting, such as the glucose
clamp. However, these methods are not suitable for large pop-
ulation studies, and, thus, surrogate estimates of insulin sen-
sitivity based on measurements in a single blood sample have
been developed. Recently an index based on the logarithm and
the reciprocal of the insulin-glucose product (QUICKI) has
been proposed. QUICKI correlated with insulin sensitivity
across the entire spectrum of glucose tolerance, but its per-
formance was less satisfactory in normal subjects. Aim of this
study was to ascertain whether the inclusion of fasting plasma
free fatty acids concentration into QUICKI improves its as-
sociation with insulin sensitivity in nonobese subjects. To test
this hypothesis, we performed a euglycemic hyperinsulinemic
clamp [40 mU/(m2min)] in 57 young, healthy, nonobese indi-
viduals with (n 17) or without (n 40) first-degree relatives
affected by type 2 diabetes (the former group being an in vivo
model of mild insulin resistance). We then compared the
clamp-based index of insulin sensitivity with both QUICKI
and a revised QUICKI, the latter index including the contri-
bution of fasting free fatty acid concentration as well. The
revised QUICKI considerably improved the relationship with
the clamp-based index of insulin sensitivity (r  0.51, P <
0.0001) with respect to QUICKI (r 0.27, P < 0.05). In addition,
the revised QUICKI revealed a reduction of insulin sensitivity
in the offspring of type 2 diabetes (10%; P < 0.006) that QUICKI
was unable to detect (3%; P  0.28). In conclusion, this study
suggests that the incorporation of fasting free fatty acid level
into QUICKI is useful to improve its correlation with the
clamp-based index of insulin sensitivity and its discrimina-
tory power in case of mild insulin resistance. Further inves-
tigation is needed to ascertain its applicability to patients
with obesity and type 2 diabetes. (J Clin Endocrinol Metab 86:
4776–4781, 2001)
INSULIN RESISTANCE IS a key factor involved in thepathogenesis of type 2 diabetes (1, 2). Longitudinal stud-
ies showed that insulin resistance is the stronger predictive
factor of the future development of the disease (2–4). It was
found to be associated with obesity, hypertension, dyslipi-
demias (5), and prevalent atherosclerosis (5–7), and the clus-
tering of these metabolic disorders is now recognized as the
insulin resistance syndrome (8, 9). The recognition of insulin
resistance therefore has investigational and clinical relevance
in the identification of subjects at high risk of developing this
syndrome.
The insulin clamp technique (10) is considered the gold
standard (11) for in vivo quantification of insulin sensitivity.
A well-accepted alternative is the minimal model analysis of
a frequently sampled iv glucose tolerance test (12), which is
less laborious but is not as simple as required in large-scale
studies.
The homeostasis model assessment index (HOMA), which
is based on the product of the fasting plasma insulin and
blood glucose concentrations measured in a single blood
sample, has been proposed as a simple and inexpensive tool
to measure insulin sensitivity (13). HOMA has been shown
to be a reliable measure of in vivo insulin sensitivity in hu-
mans when compared with the euglycemic-hyperinsuline-
mic clamp technique across the entire spectrum of glucose
tolerance (14).
Recently Katz et al. (15) showed that by taking both the
logarithm and the reciprocal of the insulin-glucose product,
one derives an index, denoted as Quantitative Insulin sen-
sitivity Check Index (QUICKI), that provides a better pre-
diction of insulin sensitivity. These authors examined nono-
bese, obese, and type 2 diabetic patients and found a very
good agreement between QUICKI and the clamp-based in-
dex of insulin sensitivity (overall r  0.78). In making sub-
group comparisons, however, they found the lowest corre-
lation coefficient (r  0.49) and the greatest variability in the
nonobese subgroup. This finding suggests that in such
groups of individuals, QUICKI still has margins of improve-
ment and that additional metabolic markers of insulin
action—besides glucose and insulin—could be profitably
taken into account to improve its association with insulin
sensitivity.
The aim of this study is to determine whether incorpora-
tion of the fasting FFA concentration into QUICKI can im-
prove the association of this index with insulin sensitivity in
nonobese subjetcs. To test our hypothesis, we performed
euglycemic hyperinsulinemic clamp studies in 57 young,
Abbreviations: CV, Coefficient of variation; GIR, glucose infusion
rate; HOMA, homeostasis model assessment index; IR, insulin resis-
tance; QUICKI, Quantitative Insulin sensitivity Check Index; SI(clamp),
glucose clamp-derived index of insulin sensitivity.
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healthy, nonobese individuals—with or without a first-
degree relative affected by type 2 diabetes mellitus—and
compared the clamp-based estimate of insulin sensitivity
with both QUICKI and a revised QUICKI, the latter index
including the contribution of fasting FFA concentration as well.
Materials and Methods
Subjects
Fifty-seven healthy, young, nonobese subjects were recruited at the
Istituto Scientifico H San Raffaele. The main criteria for their inclusion
in the study were the following: 1) age (19–45 yr); 2) white race; 3) body
mass index less than 27 kg/m2; 4) sedentary lifestyle; and 5) no history
of hypertension, endocrine/metabolic disease, or cigarette smoking.
Habitual physical activity was assessed using a questionnaire (16). Body
weight was stable for at least 6–12 months. The anthropometric char-
acteristics of the subjects are summarized in Table 1. Seventeen indi-
viduals resulted to have at least one parent with type 2 diabetes; mean-
while, the remaining 40 individuals had no family history of diabetes.
These subjects were studied to test whether incorporation of fasting FFA
concentration into QUICKI can improve its association with insulin
sensitivity. An additional subgroup of 14 healthy, nonobese subjects was
recruited to undergo a dose-response study at low and high insulin
infusion rate aimed to test whether the antilipolytic insulin action was
associated with insulin sensitivity to glucose metabolism at different
circulating insulin levels. All subjects were in good health as assessed
by medical history, physical examination, hematological assay, and uri-
nalysis. Informed consent was obtained from all subjects after expla-
nation of purposes, nature, and potential risks of the study. The protocol
was approved by the Ethical Committee of the Istituto Scientifico H San
Raffaele.
Experimental protocol
Subjects were instructed to consume an isocaloric diet and to abstain
from exercise activity for 3 wk before the studies. Women were studied
between days 3 and 8 of the menstrual cycle. Subjects were studied by
means of the euglycemic-hyperinsulinemic clamp to assess insulin sen-
sitivity after a 10-h overnight fast period. Within 2–3 d, they were also
studied by means of dual-energy x-ray absorptiometry in the Depart-
ment of Science, Nutrition, and Microbiology, Nutrition Section, Uni-
versita` degli Studi di Milano, to assess body composition.
Euglycemic-hyperinsulinemic clamp. Subjects were admitted to the Meta-
bolic Unit of the Division of Internal Medicine I of the Istituto Scientifico
H San Raffaele at 0700 h after a 10-h overnight fast. A Teflon catheter
was inserted into an antecubital vein for infusions and an additional one
was inserted retrogradely into a wrist vein for blood sampling. The hand
was kept in a heated box (50 C) throughout the experiment to allow
sampling of arterialized venous blood. Blood samples for postabsorptive
plasma glucose, insulin and FFAs were performed in triplicate. There-
after a euglycemic/hyperinsulinemic clamp was performed as previ-
ously described (17). Insulin was infused at 40 mU/[m2min] to reach a
plasma insulin concentration of about 350 pmol/liter, and plasma glu-
cose concentration was kept at 5 mmol/liter for 150 min by means of a
variable infusion of 20% dextrose infusion. Blood samples for plasma
insulin, glucose, and FFAs were drawn every 15 min throughout the
study.
Body composition. Body composition, with regional three-compartment
analysis (arms, trunk, and legs), was performed with a Lunar Corp.-
DPX-IQ scanner (Lunar Corp., Madison, WI) as previously described
(17). Fat content is expressed as kilograms of fat mass and as percent of
tissues.
Dose-response study of the antilipolytic insulin action. To assess whether
insulin sensitivity of lipolysis and glucose metabolism were associated,
a subgroup of 14 subjects (age  35  3 yr, body mass index  24.5 
1.1 kg/m2) performed a dose-response clamp study using insulin in-
fusion rates of 10 (low dose) and 40 (high dose) mU/(m2min). The
low-dose insulin clamp was designed to reach appropriate (150 pmol/
liter) plasma insulin levels to investigate the antilipolytic insulin action.
Analytical procedures
Plasma glucose was measured with a glucose analyzer (Beckman
Coulter, Inc., Fullerton, CA) (17) and coefficient of variation (CV) was
1.7  0.1% and 3.0  0.4%, respectively, in the fasting and clamp
conditions. Plasma insulin was measured with a microparticle enzyme
immunoassay technology (18) with no cross-reactions with proinsulin,
c-peptide, and glucagon (IMx insulin assay, Abbott Laboratories, Rome,
Italy). CV was 7.2 1.7% and 5.7 0.7%, respectively, in the fasting and
clamp conditions. Blood samples for FFA assessment were collected in
prechilled tubes containing 0.1% EDTA. Tubes were immediately placed
in ice and plasma was immediately processed by centrifugation at 4 C.
Plasma was then frozen and stored at 70 C, and FFA determinations
were performed as previously described (17) within 0–5 working days.
CV was 5.9 1.8% and 9.3 3.8%, respectively, in the fasting and clamp
conditions.
Calculations
Clamp-based index of insulin sensitivity. The steady-state period of the
insulin clamp was defined as the final 30-min period (i.e. 120–150 min)
during which the CV for blood glucose, plasma insulin, and glucose
infusion rate (GIR) was less than 7% and the correlation of each variable
with time was not significant. M value was defined as the GIR corrected
for the glucose added or removed from the glucose space (space cor-
rection) as previously described (10). The glucose clamp-derived index
of insulin sensitivity (SI(clamp)) was calculated as follows:
TABLE 1. Anthropometric, laboratory, and insulin sensitivity characteristics of the 57 (38F/19M) study subjects
Average SD SEM Maximum Minimum
Age (yr) 26.1 4.2 0.6 42 19
Body weight (kg) 62.1 11.5 1.5 87 41
Height (m) 1.70 0.08 0.01 1.86 1.50
Body mass index (kg/m2) 21.4 2.8 0.4 26.9 16.6
Body fat (kg) 14.9 6.2 0.8 34.1 3.8
Relative body fat (%) 24.7 8.2 1.1 41.4 7.4
Lean body mass (kg) 44.6 8.9 1.1 60.6 29.5
Fasting glucose (mmol/liter) 5.03 0.31 0.04 6.00 4.39
Clamp glucose (mmol/liter) 4.87 0.23 0.03 5.33 4.39
Fasting insulin (pmol/liter) 36.6 17.4 2.4 119.4 15.6
Clamp insulin (pmol/liter) 348.6 51.0 6.6 486.0 221.4
Fasting FFA (mmol/liter) 0.565 0.212 0.028 0.94 0.155
Clamp FFA (mmol/liter) 0.055 0.044 0.006 0.290 0.010
GIR [mg/(kgmin)] 5.43 1.47 0.19 8.49 2.66
SI(clamp) [10
4 dl/(minkg)/(U/ml)] 12.05 3.21 0.42 20.83 5.30
QUICKI 0.372 0.024 0.003 0.416 0.300
Revised QUICKI 0.418 0.047 0.006 0.573 0.327
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SI(clamp)
GIRss
Gss  Iss
(1)
where GIRss is the steady-state glucose infusion rate (mg/kg per min),
Gss is the steady-state blood glucose concentration (mg/dl) and Iss is
the difference between steady-state and basal insulin concentration
(U/ml) (19).
QUICKI. QUICKI hinges, like HOMA-IR, on the measurement of fasting
insulin and glucose concentrations. Whereas HOMA-IR is proportional
to the product of fasting insulin and glucose concentrations (13, 14),
QUICKI takes both the logarithm and the reciprocal of the glucose-
insulin product (15):
QUICKIGb, Ib
1
logGb  Ib

1
logGb logIb
(2)
where Gb (mg/dl) is the fasting glucose concentration and Ib (U/ml)
is the fasting insulin concentration. Incorporation of the fasting FFA
concentration (FFAb, measured in mmol/liter) into QUICKI leads to a
revised QUICKI, which is calculated a follows:
revised QUICKIGb, Ib, FFAb
1
logGb logIb logFFAb
(3)
Statistical analysis
All data are presented as a mean sem. The relationships SI(clamp) vs.
QUICKI and SI(clamp) vs. revised QUICKI were investigated by means of
simple regression analysis. Comparisons between the normal and the
offspring group of subjects were performed using the two-tailed un-
paired t test.
To ascertain how important the relative contribution of fasting glu-
cose, insulin, and FFA concentration to predict insulin sensitivity was,
we used the following approach: First, we expressed in a more general
way how QUICKI describes the nonlinear relationship between insulin
sensitivity and predictor variables; then, by inverting such a relation-
ship, we obtained an expression for insulin resistance as a linear com-
bination of the predictor variables, which allowed us to resort to stan-
dard regression techniques to determine their relative importance. The
expression that generalizes the way QUICKI describes the relationship
between insulin sensitivity (IS) and predictor variables is given by:
ISx1, x2,. . . xn
1
c0
i1
n
ci logxi

1
c0
i1
n
ciyi
(4)
where n is the number of the biochemical variables that contribute to the
assessment of insulin sensitivity, xi is the generic biochemical variable
measured in the fasting state, yi  log(xi) is its logarithmic transforma-
tion, and ci (i  0,1,. . . ,n) are constant coefficients that “weight” each
variable with respect to the others. Of note is that QUICKI and revised
QUICKI are both particular cases of Eq. 4 with weights c0  0 and ci 
1 for i 1. If one refers to the inverse of IS [i.e. insulin resistance (IR)],
it becomes simpler to ascertain which variables are more informative. In
fact, by taking the inverse of the two members of Eq. 4 one has:
IRx1, x2,. . . xn c0
i-1
n
ciyi (5)
Eq. 5 states that the relationship between IR and the predictor variables
is linear and thus is well suited for being analyzed by standard regres-
sion analysis techniques. We used simple regression analysis to deter-
mine the association between IR (calculated as the inverse of SI(clamp))
and log(Ib), log(Gb), and log(FFAb), separately. Then we used forward
and backward stepwise regression (using F ratio-to-remove of 4 and F
ratio-to-enter of 3.996) to assess which of these variables were more
relevant as predictors.
Results
Anthropometric and laboratory characteristics of the
study subjects
The anthropometric data of the study subjects are sum-
marized in Table 1 together with the plasma glucose, insulin,
and FFA concentrations measured in the fasting and insulin-
stimulated conditions.
Indices of insulin sensitivity
Clamp-based indices of insulin sensitivity. Clamp-based index of
IS are reported in Table 1. As expected, SI(clamp), M value, and
GIR were very well correlated with one another (r 0.83, P
0.0001). In addition, both SI(clamp) (r  -0.40, P  0.01) and
GIR (r  -0.58, P  0.0001) were inversely associated with
fasting FFA.
Relationship between the clamp-derived indices of insulin sensi-
tivity and HOMA. HOMA-IR was weakly associated with
SI(clamp) (r 0.23, P 0.09). The relationship was significantly
improved when fasting FFA was incorporated (r  0.47, P 
0.0002).
Relationship between the clamp-derived indices of insulin sensi-
tivity and QUICKI. QUICKI was associated with SI(clamp) (Fig.
1, left panel: r  0.27, P  0.05) but poorly with GIR (r  0.23,
P 0.08). The use of the revised QUICKI markedly improved
the relationships with both SI(clamp) (Fig. 1, right panel: r 
0.51, P  0.0001) and GIR (r  0.62, P  0.0001). The revised
QUICKI was associated with SI(clamp) also when data were
separately plotted in men (r  0.65, P  0.01), women (r 
0.41, P  0.01), offspring of type 2 diabetic parents (r  0.56,
P 0.02), and individuals without family history of diabetes
(r  0.45, P  0.004).
Comparison between offspring of type 2 diabetic parents
and controls
To compare the ability of the revised QUICKI with re-
spect to the QUICKI to detect differences in insulin sen-
sitivity between normal subjects and the offspring of type
2 diabetic parents, a randomized selection of 17 control
subjects was performed to obtain tight matching of anthro-
pometric characteristics (Table 2). Fasting plasma glucose
and FFA concentrations were significantly increased in the
offspring of type 2 diabetic parents with respect to the
normal subjects, whereas insulin concentrations were
comparable both in the fasting and clamp condition. Im-
paired insulin sensitivity in the offspring of type 2 diabetic
parents was reflected by 21% and 20% reduction in GIR
and SI(clamp), respectively, with respect to normal subjects.
Whereas HOMA-IR and QUICKI did not detect any sig-
nificant difference in insulin sensitivity between the two
groups, the revised QUICKI found a significant reduction
in insulin sensitivity in the offspring group (10%).
Dose-response study of the antilipolytic insulin action
During the low-dose euglycemic hyperinsulinemic clamp,
circulating insulin levels increased from 43  4 to 163  14
pmol/liter; meanwhile, during the high-dose clamp, plasma
insulin increased similarly to the previous protocol. GIRs
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were 2.62  0.20 and 6.13  0.53 mg/(kgmin), respectively,
during the low- and high-dose clamps. Fasting FFA levels
(0.577  0.077 mmol/liter) decreased by 64  5% (0.205 
0.035 mmol/liter) during the low-dose and by 84  5%
(0.094  0.014 mmol/liter) during the high-dose study. FFA
levels during the low-dose insulin clamp (which is more
appropriate to study the antilipolytic insulin action) were
inversely associated with the SI(clamp) calculated during both
the low- (r  - 0.57, P  0.033) and high-dose insulin clamp
(r  - 0.58, P  0.028).
Linear regression analysis
Table 3 shows the results of the simple and multiple step-
wise regression analysis between IR (IR 1/SI(clamp)) and the
metabolic predictor variables (e.g. log[Ib], log[FFAb], and
log[Gb]). Simple regression analysis showed that, when
taken separately, log(Ib) and log(FFAb) were significantly
associated with IR, whereas log(Gb) was not. The multiple
stepwise regression analysis selected log(Ib) and log(FFAb) as
the best set of predictors of IR.
Discussion
The results of the present study show that incorporation
of fasting plasma FFA concentration into QUICKI improves
its association with insulin sensitivity in healthy, nonobese
individuals. There are three observations supporting the
beneficial effect of calculating a revised QUICKI that in-
cludes the contribution of the fasting FFA concentration.
First, the revised QUICKI considerably improved the rela-
tionship with SI(clamp) with respect to QUICKI (Fig. 1). Sec-
ond, the revised QUICKI was able to detect a reduction in
insulin sensitivity (P  0.01)—that QUICKI was unable to
detect (P 0.27)—in a subgroup of individuals with a parent
affected by type 2 diabetes in comparison with a subgroup
of matched individuals without family history of diabetes
(Table 2). Third, the results of the multiple regression anal-
ysis indicate that the fasting FFA concentration gives a sig-
nificant contribution to improve the ability of QUICKI to
predict insulin sensitivity (Table 3).
QUICKI is an attractive approach to measure insulin sen-
sitivity in population studies because it is based on a single
blood sample and is well correlated with the clamp-based
estimate of insulin sensitivity (15). However, QUICKI seems
to be less efficient when used to measure insulin sensitivity
in the normal range (15). Additional supporting evidence
comes from the present study in which we found that
QUICKI was unable to detect differences in insulin sensi-
tivity between groups of nonobese individuals with or with-
FIG. 1. Correlation between SI(clamp) and QUICKI (left panel) and between SI(clamp) and revised QUICKI (right panel). Offspring of type 2 diabetic
parents are represented by the empty circles, normal subjects are represented by the full circles.
TABLE 2. Comparison between the offspring of type 2 diabetic parents and controls
Offspring Normals P
n (M/F) 17 (9F/8M) 17 (9F/8M)
Age (yr) 26.5  1.1 25.4  1.1 0.48
Body mass index (kg/m2) 21.6  0.6 21.8  0.8 0.89
Relative body fat (%) 22.8  1.8 24.6  1.8 0.49
Fasting glucose (mmol/liter) 5.15  0.08 4.93  0.06 0.05
Fasting insulin (pmol/liter) 40.2  6.0 32.4  3.0 0.26
 insulin (pmol/liter) 321.0  10.2 333.0  13.8 0.48
Plasma free fatty acids (mmol/liter) 0.634  0.065 0.481  0.051 0.03
GIR [mg/(kgmin)] 4.85  0.25 6.11  0.32 0.004
SI(clamp) [10
4 dl/(minkg)/(U/ml)] 10.31  0.50 12.89  0.58 0.001
QUICKI 0.368  0.007 0.378  0.005 0.28
Revised QUICKI 0.400  0.009 0.439  0.010 0.006
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out family history for type 2 diabetes, the former group
having a significant 20% reduction in insulin sensitivity,
according to the euglycemic hyperinsulinemic clamp. The
finding that QUICKI is less powerful when applied to non-
obese subjects is probably related to the fact that in this group
of individuals, fasting glucose and insulin are both within
narrow ranges, which makes it difficult for QUICKI to span
with accuracy the wide spectrum of insulin sensitivity char-
acterizing normal individuals. These difficulties motivated
our search for an additional postabsorptive metabolic
marker of insulin action that could improve the ability of
QUICKI to measure insulin sensitivity. We hypothesized that
the fasting FFA level might be useful to this purpose because
1) in healthy normal subjects considered to be at high risk of
developing diabetes—offspring of type 2 diabetic parents—
the postabsorptive plasma FFA concentration was increased
in the presence of normal plasma glucose and insulin levels
(8, 17, 20, 21); 2) lipolysis is very sensitive to insulin, being
that a half-maximal effective dose of insulin for suppression
of lipolysis is about 50% of that for suppression of endoge-
nous glucose production (22, 23); and 3) the dose-response
study performed in an additional subgroup of 14 individuals
showed that FFA levels during the low-dose insulin clamp
were inversely associated with SI(clamp) both during the low-
and high-dose insulin clamp.
The use of fasting FFA level was beneficial to QUICKI
because it strengthened its association with insulin sensitiv-
ity (Fig. 1) and also increased its discriminatory power, en-
abling it to detect a difference in insulin sensitivity between
the individuals with or without family history of diabetes
(Table 2). The latter finding is of particular importance if
QUICKI is to be used in population studies aiming to identify
groups at risk of developing diabetes in which the impair-
ment of insulin sensitivity is at an early stage.
The importance of the contribution of FFA concentration
to QUICKI was further corroborated by the results of the
regression analysis. In our group of nonobese subjects, we
found that insulin concentration is the most important
correlate of insulin resistance; FFA concentration yields
additional, independent information that significantly im-
proves the association with insulin resistance; and glucose
concentration has only a minor, nonsignificant role. We
speculate that the relative unimportance of glucose as
predictor of IR is due to the fact that in normal subjects the
glucose-insulin homeostatic system is successful in main-
taining glycemia within a very narrow range. It is plau-
sible that the role of glucose as predictor of IR may be more
important in obese individuals and in type 2 diabetic pa-
tients (i.e. in groups in which the homeostatic loop is
disturbed).
This study in normal subjects represents a prerequisite,
and further work is needed to ascertain whether including
the fasting FFA concentration into QUICKI can be useful
throughout the entire spectrum of glucose tolerance. What
needs to be assessed is whether FFA concentration is still
a source of meaningful, independent information on in-
sulin sensitivity also in groups with a higher degree of
insulin resistance. Anyway, it is encouraging to find ev-
idence in the literature suggesting that fasting FFA con-
centration might be helpful in the prediction of insulin
resistance also in obese and type 2 diabetic patients. In fact,
it has been observed that obese patients with type 2 dia-
betes mellitus have impaired regulation of lypolisis (23,
24), and that in vivo experimental increments of plasma
FFA concentrations in healthy humans can induce an IR
similar to that observed in type 2 diabetes (25, 26).
In conclusion, this work represents the first attempt to
include other metabolic markers, in addition to fasting glu-
cose and insulin, to obtain a more accurate prediction of
insulin sensitivity based on a fasting blood sample. Incor-
poration of the fasting FFA concentration into QUICKI not
only improved its association with insulin sensitivity but also
enhanced its discriminatory power. Thus, incorporation of
the fasting FFA concentration into QUICKI may be helpful
for earlier identification of metabolic abnormalities in at-risk
subjects and, if validated also in disease states, may contrib-
ute to a more widespread use of QUICKI in large-scale or
epidemiological studies.
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